Glaxo to miss growth targets
Friday 30 July 1999
At its annual meeting in May, Glaxo said it was on track, even though first-quarter sales were been worse than expected.
Yesterday it blamed disappointing sales of Imitrex, a migraine drug, and Zyban, which helps people give up smoking, and weak Asian markets for abandoning its goals. It had previously expected Imitrex and Zyban to offset declining revenues from Zantac, the anti-ulcerant which lost its patent in 1997.
Sir Richard Sykes, chairman, said Glaxo could not promise to deliver 10 per cent profits growth in constant currency terms, but there could be a beneficial effect from the millennium. "I am not happy to say we're not going to meet the commitment, which we have had on the table for over two years," he said.
Between a week's and a month's sales could be brought forward ahead of the millennium because of worries the Y2K bug will hit medical supply chains, he said. The company had still believed in May it could meet its goals, he added. Imitrex was expected to benefit from marketing campaigns by rivals, but this had not happened. Glaxo is now to boost its 4,000- strong US sales force by about 1,000 people.
There was no question of people resigning, Glaxo said. "I hope I don't sound arrogant, but I never considered resigning," said chief executive Robert Ingram. "We wanted a challenge. We could have fudged it, but we're not doing that." The shares fell 199p to 1553p.
The magicians using online collaboration to push boundaries
Jennifer Lawrence attacks mass media again over body image
Jennifer Lawrence: 'It should be illegal to call someone fat on TV'
Sun will 'flip upside down' within weeks, says Nasa
Ian Watkins: Police forces probed over earlier allegations as paedophile Lostprophets singer sentenced to 35 years for child sex offences
DNA from a 50,000 year old toe shows Neanderthals were highly inbred
Devyani Khobragade: India-US row escalates over arrest of diplomat in New York
- 1 America's 'virgin births'? One in 200 mothers 'became pregnant without having sex'
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 4 Christmas comes early: Justin Bieber announces he's 'retiring from music'
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
iJobs Money & Business
£25000 - £32000 per annum: Harrington Starr: Junior Business Analyst - Banking...
£25000 - £35000 per annum + benefits + bonus: Harrington Starr: Business Analy...
£50000 - £75000 per annum + benefits + bonus: Harrington Starr: Implementation...
£50000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: A leading prov...